BioPharma Charter

The opportunity for Sponsors and CROs to transform remote cardiac monitoring for improved data collection and patient satisfaction.

Solutions for


Leverage customizable digital health solutions to provide patient heart rhythm data, anytime and anywhere

“The landscape of clinical research is quickly evolving with the rise of remote monitoring tools like KardiaMobile 6L. The AliveCor digital ECG solution enables trial design flexibility for follow-up visits, or even full decentralization, without impacting data quality.

It’s also very easy to use, making it very appealing to trial participants. The KardiaMobile 6L dramatically expands our ability to collect ECG data from outpatients in clinical trials or even in clinical practice.”

Dr Robert Kleiman

Chief Scientific and Regulatory Advisor, Cardiac Safety, Clario

Trusted Mobile ECG Data and QT Measurement


FDA-cleared 6-lead mobile ECG device


clinical publications


ECGs collected with Kardia devices

HIPAA and GDPR compliance

Our Partners

Leading and specialized biopharma companies, CROs, academic centers, and government agencies work with AliveCor to advance their digital ECG solutions:

R&D Solutions

Clinical Research

Simplicity that provides medical-grade ECG data & reduces burden

Over 80% of clinical trials do not reach their recruitment targets within their specified timeframe, creating trial delays and increased costs.1,2

We aim to change that with digital ECG solutions that support the highest caliber of clinical research. The most clinically validated personal ECG device, KardiaMobile 6L makes it easy for patients to record an ECG in 30 seconds and has demonstrated high patient adherence with mobile ECGs in clinical trials.3 Unlock access to trusted mobile heart data in decentralized, hybrid, and traditional clinical trials and streamline data analysis with EHR, API, and SDK data integration options or use our proprietary platform.

See how easy it is to use KardiaMobile 6L

Accurate advanced determinations, including AFib, QT interval, and much more*

Proven high patient adherence with mobile ECGs in DCTs3,4

Trusted by leading global pharma companies and CROs for use in clinical research

Drive diversity in clinical trials with decentralized and hybrid trial design

Easily integrate trial data using AliveCor API and FDA-cleared SDK, or proprietary platform

Learn how KardiaMobile 6L is being used in clinical research today.

AFib Monitoring in DCT

DeTAP Study evaluated oral anticoagulation therapy for Atrial Fibrillation (Afib).

Remote monitoring of 100 participants in single-arm trial design with KardiaMobile 6L demonstrated:

  • Rapid recruitment (100 participants in 28 days, >300 waitlisted)
  • High engagement 99% ECG completion

QT Interval Monitoring in DCT

Study4 evaluated efficacy of COVID-19 treatment required cardiac safety monitoring of the QT interval.

Multi-center randomized clinical trial was fully remote, monitored the QT interval for 231 participants (3,256 ECGs), and demonstrated:

  • 85% adherence to daily ECGs over 2 weeks
  • Effectiveness of digital tools (i.e. KardiaMobile 6L) to conduct rigorous, safe, fully remote clinical trials

We help you achieve your clinical research goals, quickly and cost-effectively

Commercial Solutions

Cardiac Safety Monitoring (CSM)

Remove barriers to prescribing medications that impact heart rhythm

Certain medications can cause cardiac arrhythmias. For example, tyrosine kinase inhibitors (TKIs) are associated with atrial fibrillation, and sphingosine 1-phosphate (S1P) receptor modulators cause QT prolongation which can lead to dangerous arrhythmias. As a result, many healthcare professionals are wary of prescribing these medications, due to the burden associated with cardiac monitoring.

AliveCor BioPharma enables streamlined, reimbursable in-office ECG screening that provides cardiac rhythm determinations — including atrial fibrillation, bradycardia, tachycardia, PVCs and more — in just 30 seconds.

We have successfully launched U.S. and global programs that enable healthcare professionals to use both in-office and at-home monitoring to screen for and monitor cardiac arrhythmias

Benefits of becoming a CSM partner
  • Increase confidence among target physicians to prescribe medications that cause arrhythmias
  • Enable reimbursable, streamlined in-office ECGs with medical-grade results and InstantQT in just 30 seconds
  • Leverage the #1 doctor-recommended and patient-preferred personal ECG device
  • Provide key heart rhythm data to enable prescribing medications to appropriate patients
  • Enable patients to engage in their own care and eliminate unnecessary office visits by monitoring at home

Commercial Solutions

Drugs+ and Beyond the Pill Programs

Enhance your Rx brand with innovative digital health strategies

We partner with prescription brands to develop customized digital health solutions that include virtual cardiology and remote patient monitoring platforms. Our remote monitoring devices, apps, and solutions can be used for patient screening, disease monitoring, medication management and more.

Improve Rx management with remote ECG monitoring

Leverage ECG data to develop new algorithms and conduct market research

Enable ongoing patient monitoring of cardiac conditions to improve delivery of critical medications

Screen, monitor and manage Rx safety and efficacy with remote monitoring devices, apps and services

Get started

Explore partnership opportunities with AliveCor BioPharma

ECG Monitoring

Plug & Play Digital Tools

    KardiaMobile<sup>®</sup> 6L

KardiaMobile® 6L

The #1 doctor-recommended and patient-preferred 6-lead personal ECG, KardiaMobile 6L is FDA-cleared to provide medical-grade heart rhythm data, anytime and anywhere. With no wires, patches or gels, the device easily captures six leads of patient heart data, either remotely or onsite.



KardiaRx is an iOS/Android app which enables remote ECG capture and monitoring in decentralized clinical trials. When the app pairs with KardiaMobile 6L, patient ECGs are automatically uploaded to KardiaPro, our web-based portal, or another preferred EDC platform — for 24/7 access to critical cardiac rhythm data.



KardiaStation by AliveCor BioPharma allows healthcare professionals and clinical teams to record, store and review six leads of patient ECG data, right in their office, using KardiaMobile 6L. KardiaStation can instantly display QT interval measurements** to help physicians more confidently prescribe QT-prolonging medications.



Securely manage and review ECG data captured with KardiaMobile 6L on our HIPAA-compliant, SOC-2 certified, web-based portal.

KardiaMobile 6L provides instant, automated cardiac rhythm determinations

  • Atrial fibrillation
  • Bradycardia
  • Tachycardia
  • QT/QTc/QTcF**
  • HR and RR
  • Sinus Rhythm with SVE
  • Sinus Rhythm with PVCs
  • Sinus Rhythm with Wide QRS

Our Team

Our BioPharma management team offers over 70 years of combined experience in leading Top 10 Pharma & CRO companies. And our front- and back-end engineers have the technical expertise needed to help fully support our partners across any project.

David Zied

David Zied

VP, Global BioPharma Partnerships

David is an experienced pharmaceutical executive with more than 25 years in sales, marketing and operational leadership roles with several of the world’s leading pharmaceutical companies, including GSK, BMS, Bayer and Eisai. After working across several therapeutic areas including neurology, mental illness, cardiology and 15+ years in oncology, David joined AliveCor from Novartis Oncology, where he was responsible for developing innovative digital solutions through strategic partnerships with startups, including AliveCor. As the VP of Global BioPharma Partnerships, David works closely with Pharma clients to develop and launch brand-focused digital solutions to enable brand growth and improve patient access worldwide.

Tom Flaherty

Tom Flaherty

Director, Cardiac Digital Solutions, BioPharma Sales

Tom is a highly regarded voice in the biopharma industry with extensive experience in clinical trial research and business development spanning over 20 years. With a strong background in cardiovascular and CNS, he specializes in consulting with pharmaceutical companies and CROs to implement device and biosensor strategies and integrations into their studies and clinical trials. Tom joined AliveCor after holding business development roles with prestigious, globally recognized companies focusing on clinical trial research, including Verily and Philips Healthcare. His focus and passion are to consult and partner with Pharma and CROs to utilize Alivecor's vast cardiovascular solutions and innovation to improve the patient and HCP experience within the clinical trial setting.

Arush Pandya

Arush Pandya

Senior Director, Global BioPharma Product Management

Arush is a Product Manager, innovator, and entrepreneur who is passionate about finding solutions to consumer-centric problems in the healthcare industry. He is currently the Senior Director of Product Management for Global BioPharma at AliveCor where he oversees development and implementation of technical solutions to enable cutting-edge ECG recording technologies for clinical trials, cardiac safety monitoring programs, and DTx programs. Arush has over 25 years of experience in the pharmaceutical industry.

Hager Elgedawe

Hager Elgedawe

Global Clinical Implementation Lead

Hager is a clinical research professional with over 10 years of experience running clinical trials in oncology, hematology, and cardiothoracic surgery at nationally renowned institutions including the Seattle Cancer Care Alliance, and Columbia University. She is currently the Global Clinical Implementation Lead at Alivecor, working with institutional and industry partners to utilize Alivecor’s innovative Kardiamobile 6L device in both clinical trials and post registration programs.

Partner with AliveCor BioPharma to benefit from our specialized ECG digital health solutions


*KardiaMobile 6L does not check for heart attack.
**QT measurements made using EK12 ECG algorithm.
†AliveCor makes no guarantee, promise, or direct instruction regarding billing, coverage, or reimbursement. Accurate coding and claims submission practices are the sole responsibility of the health care provider.

1. Huang GD, et al. Contemporary Clinical Trials March 2018(66) pp 74-79.
2. Chaudhari N et al. Perspect Clin Res. 2020 Apr-Jun; 11(2): 64-69.
3. Sarraju A et al. Npj Digital Medicine (2022)5:80.
4. Mayfield JJ et al. Commun Med (Lond). 2021 Dec 20;1:62.